Akorn, Inc. (NASDAQ:AKRX), a leading specialty generic pharmaceutical company, today announced that Gregory P. Lawless joined Akorn as Chief Human Resources Officer onJanuary 18, 2016.
Mr. Lawless joins Akorn from The Kraft Heinz Company, where he served most recently as Vice President, Human Resources over his 13 years at the company. In his most recent role at Kraft Heinz, Mr. Lawless was responsible for human resources needs for the company’s Global Operations organization. Mr. Lawless began his distinguished career in human resources at Philip Morris USA. Mr. Lawless holds a B.A. in Economics and Government from Colby College.
“Greg is an accomplished executive with over 25 years of experience in human resources at Fortune 500 companies and we are pleased to bring his skills and background to Akorn to lead our global HR team,” said Raj Rai, Akorn’s Chief Executive Officer. “I look forward to Greg’s leadership and contributions to support our global workforce and growth initiatives.” (Original Source)
Shares of Akorn Inc closed yesterday at $28.07. AKRX has a 1-year high of $57.10 and a 1-year low of $19.08. The stock’s 50-day moving average is $34.76 and its 200-day moving average is $35.91.
On the ratings front, Akorn has been the subject of a number of recent research reports. In a report issued on January 15, Craig-Hallum analyst Matt Hewitt maintained a Buy rating on AKRX, with a price target of $45, which implies an upside of 60.3% from current levels. Separately, on January 13, Nomura’s Shibani Malhotra maintained a Buy rating on the stock and has a price target of $46.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Matt Hewitt and Shibani Malhotra have a total average return of 86.6% and 16.3% respectively. Hewitt has a success rate of 50.0% and is ranked #428 out of 3579 analysts, while Malhotra has a success rate of 56.8% and is ranked #225.
The street is mostly Bullish on AKRX stock. Out of 5 analysts who cover the stock, 5 suggest a Buy rating . The 12-month average price target assigned to the stock is $45.75, which represents a potential upside of 63.0% from where the stock is currently trading.
Akorn Inc manufactures and markets a full line of diagnostic and therapeutic ophthalmic pharmaceuticals as well as niche hospital drugs and injectable pharmaceuticals.